Inflammatory and structural sacroiliac MRI lesions at baseline, after 6 months and after 12 months
| Inflammatory lesions | Baseline (n=35) | Month 6 (n=33) | Month 12 (n=5) | ||||||
| Subjects with ≥1 lesion (n, %) | Range (min–max) | Median (95% CI) | Subjects with ≥1 lesion (n, %) | Range (min–max) | Median (95% CI) | Subjects with ≥1 lesion (n, %) | Range (min–max) | Median (95% CI) | |
| Sacroiliitis (ASAS definition) | 21 (60) | – | – | 5 (15) | – | – | 4 (80) | – | – |
| SPARCC score | 27 (77) | 0–30 | 5 (1 to 8) | 15 (46) | 0–16 | 0 (0 to 1) | 4 (80) | 0–14 | 4 (0 to 4) |
| Capsulitis | 4 (11) | 0–12 | 0 (0 to 0) | 0 | 0–0 | 0 (0 to 0) | 0 | 0–0 | 0 (0 to 0) |
| Enthesitis | 1 (3) | 0–2 | 0 (0 to 0) | 0 | 0–0 | 0 (0 to 0) | 0 | 0–0 | 0 (0 to 0) |
| High signal intensity joint space | 13 (37) | 0–12 | 0 (0 to 1) | 4 (12) | 0–10 | 0 (0 to 0) | 0 | 0–0 | 0 (0 to 0) |
| Structural lesions | |||||||||
| Sclerosis | 4 (11) | 0–13 | 0 (0 to 0) | 4 (12) | 0–10 | 0 (0 to 0) | 3 (60) | 0–13 | 1 (0 to 6) |
| Erosions | 1 (3) | 0–1 | 0 (0 to 0) | 2 (6) | 0–2 | 0 (0 to 0) | 1 (20) | 0–3 | 0 (0 to 3) |
| Fatty lesions | 0 | 0–1 | 0 (0 to 0) | 5 (15) | 0–10 | 0 (0 to 0) | 1 (20) | 0–5 | 0 (0 to 5) |
| (Partial) ankylosis | 0 | 0–0 | 0 (0 to 0) | 0 | 0–0 | 0 (0 to 0) | 0 | 0–0 | 0 (0 to 0) |
ASAS, Assessment of SpondyloArthritis International Society; SPARCC, Spondyloarthritis Research Consortium of Canada.